Verastem | VSTM - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 5.81B 1.23B 2025-12
Alaunos Therapeutics USD -1.19M 148K 2025-09
AstraZeneca USD 2.97B 4.48B 2025-12
Curis USD -7.88M 4.63M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Laboratory Of America USD 382M 15.3M 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Verastem USD -41.48M 23.2M 2025-12